|
IND candidate EPI-7386 as an N-terminal domain androgen receptor inhibitor in development for the treatment of prostate cancer. |
|
|
No Relationships to Disclose |
|
|
Stock and Other Ownership Interests - ESSA |
|
|
Stock and Other Ownership Interests - ESSA |
|
|
No Relationships to Disclose |
|
|
Stock and Other Ownership Interests - ESSA |
|
|
Consulting or Advisory Role - ESSA |
Patents, Royalties, Other Intellectual Property - ESSA |
|
|
|
Stock and Other Ownership Interests - ESSA |
Consulting or Advisory Role - ESSA |
|
Patents, Royalties, Other Intellectual Property - ESSA |
|
Travel, Accommodations, Expenses - ESSA |
|
|
Employment - ESSA; NanoString Technologies |
Stock and Other Ownership Interests - ESSA; NanoString Technologies |
Consulting or Advisory Role - Arch Oncology; Refuge Biotech |
Travel, Accommodations, Expenses - ESSA; NanoString Technologies |
|
|
|
Stock and Other Ownership Interests - ESSA |
Consulting or Advisory Role - ESSA |
|
Patents, Royalties, Other Intellectual Property - ESSA |
Expert Testimony - Pfizer |
Travel, Accommodations, Expenses - ESSA |
|
|
|
Stock and Other Ownership Interests - ESSA |
Travel, Accommodations, Expenses - ESSA |
|
|
|
Stock and Other Ownership Interests - ESSA |
Travel, Accommodations, Expenses - ESSA |